Tianjin Lisheng Pharmaceutical Co., Ltd. Class A
SSZSE:00239313.17
CNY
-0.02
(-0.15%)
ISIN
CNE100000NJ9
Return %
Stock
S&P 500
1Y
-33.18
13.14
3Y
-5.24
80.78
5Y
18.00
67.74
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Fu Jun Wang
- Full Time Employees
- 1,605
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No.16, Saida North 1st Road Tianjin TI China 300385
- IPO Date
- Apr 26, 2010
- Website
- lishengpharma.com
- Similar Companies
- Business
- Tianjin Lisheng Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, production, and sale of a wide range of pharmaceutical products. Founded in 1951 and headquartered in Tianjin, China, the company operates primarily in the medical and health industries, offering products in multiple forms including tablets, hard capsules, pills, freeze-dried powder injections, water injections, oral liquids, granules, films, biological agents, and active pharmaceutical ingredients (APIs). Its core product categories cover cardiovascular and cerebrovascular drugs, anesthetics, analgesics, anti-infective agents, antineoplastic and immune system drugs, endocrine and respiratory medications, digestive system medicines, genitourinary system treatments, and traditional Chinese medicines. Key brands include "Shoubishan" indapamide tablets, "Shifuni" cefdinil dispersible tablets, and various soft capsules such as those based on hemp seed extract. The company’s product portfolio spans 15 pharmaceutical categories with over 243 approved drug registrations. Tianjin Lisheng operates a comprehensive industrial layout integrating research, development, manufacturing, and marketing, servicing both domestic and international markets with a broad sales network across China and exports to global markets. It also provides one-stop contract manufacturing organization (CMO) services to support pharmaceutical innovation ecosystems, particularly in Tianjin. As a national high-tech enterprise and national green factory, it adheres to advanced sustainability and innovation standards. In terms of recent major developments, Tianjin Lisheng Pharmaceutical announced an equity buyback program worth approximately CNY 153 million in 2024 to optimize its capital structure. The company continues to focus strategically on expanding its product offerings in critical therapeutic areas such as cardiovascular health and anti-infectives while advancing its capabilities in biopharmaceutical production. It actively pursues "industrial operation plus capital operation" dual-drive strategies, enhancing its competitiveness through innovation and strategic capital deployment. The company also maintains active participation in clinical trials and drug pipeline development to strengthen its therapeutic arsenal. Tianjin Lisheng Pharmaceutical Co., Ltd. is a subsidiary of Tianjin Jinhao Pharmaceutical Co., Ltd. and maintains significant brand recognition and market presence in China’s pharmaceutical industry. The company has received multiple accolades such as recognition as a Model Socially Responsible Enterprise in Tianjin and awards for its high-quality antihypertensive product brands. Its operations and offerings contribute broadly to China's healthcare and pharmaceutical sectors. Overall, Tianjin Lisheng Pharmaceutical is a well-established, diversified pharmaceutical enterprise with a long history, focused product lines across key therapeutic areas, ongoing strategic growth initiatives, and a commitment to innovation and sustainability in its industry presence.